A Liquid Biopsy is a non-invasive medical test that involves analyzing a sample of body fluids, typically blood, to obtain information about a person’s health status. Unlike traditional biopsies, which involve extracting tissue samples through surgical procedures, liquid biopsies provide valuable insights into various aspects of health and disease through the analysis of molecules present in the bodily fluids.
The MagSi-cfDNA kit is intended for Liquid Biopsy, the (automated) purification of circulating cell-free DNA from human plasma, serum or urine samples. Processing time for the preparation of 24 samples is about 60 minutes.
Safety
The kit requires no phenol/chloroform extraction or alcohol precipitation and eliminates the need for repeated centrifugation, vacuum filtration or column separation. It allows safe handling of potentially infectious samples. The obtained cfDNA can be used directly for downstream applications such as qPCR, or any kind of enzymatic reaction.
Figure 1. cfDNA yield from various volumes of serum and Streck plasma. cfDNA was quantified using an Agilent TapeStation 4150 assay (cell-free DNA assay). High cfDNA yields were obtained in a scalable way.
Figure 2. cfDNA yield from serum and Streck plasma samples. For serum, high yields (average of 2) were obtained in comparison to a competitor kit. The cfDNA yield was lower when plasma samples were used but the cfDNA percentage was higher (magtivio 64.6% vs T 60.5%).
Figure 3. Automated electrophoresis by Agilent TapeStation 4150 showing high integrity of purified cfDNA from frozen a) serum and b) Streck plasma samples.
Figure 4. Typical electropherograms of purified cfDNA from human plasma collected in Streck BCT tubes (a) magtivio (b) competitor product T. High quality of cfDNA was obtained with the magtivio kit whereas the competitor kit shows high molecular weight DNA contamination (highlight).